{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Rapport Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"RAPP"},"Address":{"label":"Address","value":"1325 BOYLSTON STREET,,SUITE 401, BOSTON, Massachusetts, 02215, United States"},"Phone":{"label":"Phone","value":"857-321-8020"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts."},"CompanyUrl":{"label":"Company Url","value":"www.rapportrx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Abraham N. Ceesay","title":"President, Chief Executive Officer & Director"},{"name":"Bradley S. Galer","title":"Chief Medical Officer"},{"name":"Cheryl Gault","title":"Chief Operating Officer"},{"name":"David Bredt","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}